Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APX3330 |
| Synonyms | |
| Therapy Description |
APX3330 (E3330) inhibits redox factor 1 (REF1, APEX1), potentially resulting in decreased tumor angiogenesis and increased apoptosis and reduced viability, and proliferation of tumor cells (PMID: 19097035, PMID: 28446640, PMID: 31413178). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APX3330 | APX-3330|APX 3330|E3330|E 3330 | APX3330 (E3330) inhibits redox factor 1 (REF1, APEX1), potentially resulting in decreased tumor angiogenesis and increased apoptosis and reduced viability, and proliferation of tumor cells (PMID: 19097035, PMID: 28446640, PMID: 31413178). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03375086 | Phase I | APX3330 | A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330) | Completed | USA | 0 |